This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma

    Provides prognostic grading system for tumor cells based on physical cellular appearance.
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with clear cell RCC and pathology assessment available.

    The Fuhrman Nuclear Grade is a pathology component of renal cell cancers and an independent predictor of cancer-specific survival. Virtually all data are from chart or database reviews and predate modern targeted therapies, but typically worsening nuclear grade correlates with worsening prognosis.

    There are no validated scoring systems for predicting survival in clear cell RCC. Using the Fuhrman grade or scoring systems that integrate it may help delineate categories of survival time better than clinical judgment alone.

    Small (~10µm)
    Larger (~15µm)
    Even larger (~20µm)
    Round, uniform
    Irregularities in outline
    Obvious irregular outline
    Absent, inconspicuous
    Visible at x400
    Prominent at x100
    No
    Yes

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Susan A. Fuhrman

    About the Creator

    Susan A. Fuhrman, MD, is a practicing clinical and anatomic pathologist in Columbus, Ohio. She is Director of Pathology and Lab at OhioHealth Central Laboratories. Dr. Fuhrman is best known in the scientific medical community for developing the Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma.

    To view Dr. Susan A. Fuhrman's publications, visit PubMed

    Are you Dr. Susan A. Fuhrman? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Dr. Nathalie Rioux-Leclercq

    About the Creator

    Nathalie Rioux-Leclercq, MD is the head of the Pathological Anatomy and Cytology Service, part of the Department of Pathology and a professor of medicine at Rennes University Hospital in France. Her research focuses on renal cell carcinoma. prostatic adenocarcinoma, proliferation and apoptosis in the tumor process, and was lead author on the validation and reclassification of the Fuhrman Grade.

    To view Dr. Nathalie Rioux-Leclercq's publications, visit PubMed

    Are you Dr. Nathalie Rioux-Leclercq? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    About the Creator
    Dr. Susan A. Fuhrman
    Are you Dr. Susan A. Fuhrman?
    Dr. Nathalie Rioux-Leclercq
    Are you Dr. Nathalie Rioux-Leclercq?